UK-based medical endowment Wellcome Trust is creating a £200m ($300m) investment company to invest in start-up biotechnology companies.

The company, temporarily called Sigma, will focus on UK and European transformational technologies with potential for high returns over at least a decade.

Nigel Keen, chairman of public technology companies in the healthcare and electronics industries, including Oxford Instruments, Laird, Bioquell and Deltex Medical, will be chairman of Sigma.

Martin Murphy (pictured), previously a partner at venture capital firm MVM Life Science…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?